Overprescription of short‐acting β2‐agonists among patients with asthma in Saudi Arabia: Results from the SABINA III cohort study
Abstract Despite near‐universal health care and timely updates to treatment guidelines in Saudi Arabia, asthma control remains suboptimal, warranting deeper exploration of its management practices. This study describes asthma characteristics and prescription patterns of short‐acting β2‐agonists (SAB...
Main Authors: | Hamdan Al‐Jahdali, Siraj Wali, Amr S. Albanna, Abeer Al Harbi, Riyad Allehebi, Abdulmajed Arwadi, Tarek Dahan, Mohamed Fattouh, Ezzat Hamza, Maarten Beekman |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-12-01
|
Series: | The Clinical Respiratory Journal |
Subjects: | |
Online Access: | https://doi.org/10.1111/crj.13553 |
Similar Items
-
Overprescription of short-acting β2 agonists: reflections from the SABINA study in Brazil
by: Martti Anton Antila, et al.
Published: (2024-02-01) -
A Cross-Sectional Study on Prescription Patterns of Short-Acting β2-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort
by: Pedrozo-Pupo JC, et al.
Published: (2022-08-01) -
SABA prescriptions and asthma management practices in patients treated by specialists in Taiwan: Results from the SABINA III study
by: Sheng-Yeh Shen, et al.
Published: (2022-12-01) -
Prevalence of eosinophilic, atopic, and overlap phenotypes among patients with severe asthma in Saudi Arabia: a cross-sectional study
by: Hamdan Al-Jahdali, et al.
Published: (2022-02-01) -
Over-prescription of short-acting β2-agonists for asthma in South Africa: Results from the SABINA III study
by: C Smith, et al.
Published: (2022-12-01)